Compare Lithium Americas Corp (LAC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Lithium Americas Corp trades at $2.07 (market cap $800.75M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 6.1× Lithium Americas Corp's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LAC | TVTX | |
|---|---|---|
Market Cap | $800.75M | $4.88B |
Volume | 6,634,849 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $9.44 | $67.52 |
52-Week Low | $2.07 | $26.79 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $1.14B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.20, down 2.22% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten earnings expectations in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
LAC presents a high-risk, high-reward opportunity with analyst consensus price target of $4.00 (82% upside). While current fundamentals are weak due to pre-revenue phase, successful execution at Thacker Pass could drive significant revaluation. Key risks include lithium price volatility, project execution challenges, and continued cash burn during development.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
